Showing results (21-30 of 121) with videos related to

Sort By:
Pageof 13
Communications Medicine|October 25, 2022
Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanomaXu Xiao, Qian Guo, Chuanliang Cui, et al.
Cancer Investigation|May 23, 2025
Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective AnalysisHuichun Tian, Jiaran Zhang, Lili Mao, et al.
Zhonghua Yi Xue Za Zhi|December 30, 2015
[Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma]Bixia Tang, Zhihong Chi, Xinan Sheng, et al.
NPJ Genomic Medicine|February 5, 2021
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanomaChuanliang Cui, Canqiang Xu, Wenxian Yang, et al.
Cell Death & Disease|March 16, 2019
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinomaSifan Yu, Jie Dai, Meng Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway InhibitorsYan Kong, Lu Si, Yiqian Li, et al.
Annals of Surgical Oncology|December 23, 2017
Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in ChinaSiming Li, Xinan Sheng, Lu Si, et al.
Zhonghua Yi Xue Za Zhi|December 31, 2014
[Genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib]Xinan Sheng, Yan Kong, Huan Tang, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao|January 11, 2025
Genomic characterization reveals distinct mutational landscape of acral melanoma in East AsianFenghao Zhang, Xiaowen Wu, Tao Jiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2013
Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanibJie Dai, Yan Kong, Lu Si, et al.
Pageof 13